Pharmacologic interventions for the neonate with compromised cardiac function.

L A Kulik; P A Hickey; P R Lawrence

doi:10.1097/00005237-199109000-00010

Home/Archive/PubMed

PubMed · 1880745

Pharmacologic interventions for the neonate with compromised cardiac function.

L A Kulik·P A Hickey·P R Lawrence

View original source ↗Export metadata ↓

Abstract

The developmental aspects of myocardial performance must be considered when pharmacologic agents are used to support the neonate with compromised cardiac function. Neonatal cardiovascular function is characterized by a limited preload reserve, decreased ventricular compliance, limited contractile reserve, and CO that is primarily dependent on the HR. Nurses caring for these neonates need a baseline understanding of normal cardiovascular physiology to evaluate the effectiveness of pharmacologic interventions to augment CO. Neonatal nurses play a pivotal role in the therapeutic management of pharmacologic interventions to provide safe, high quality care for the sick neonate.

Explore related subjects

Cardiovascular Agents Child Development Child, Preschool Heart Diseases Hemodynamics Humans Infant, Newborn Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

L A Kulik, P A Hickey, P R Lawrence. 1991. Pharmacologic interventions for the neonate with compromised cardiac function.. https://doi.org/10.1097/00005237-199109000-00010

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The preventive polypill--much promise, insufficient evidence.

Explore the source record for details and available documents.

Cardiovascular Agents↗

PubMed2007

Cardiovascular therapy and pharmacogenetics in 2007.

John Carlquist received a PhD from the Department of Cellular Viral and Molecular Biology at the University of Utah School of Medicine (UT, USA) with research emphasis in molecular immunology. After completion of his training, he received a faculty appointment in the Department of Internal Medicine, University of Utah, where he became interested in immune mechanisms in cardiovascular disease. He developed an interest in genetics through studies of human leukocyte antigen (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart disease. He began the Molecular Diagnostics Laboratory for Intermountain Healthcare and continues to serve as Technical Director; he also directs the Intermountain Heart Study Molecular and Genetic Research Laboratory. Current research interests include the genetics of lipid metabolism as related to coronary heart disease and the genetic factors influencing drug treatment outcomes.

Cardiovascular Agents↗

PubMed2006

Ensuring that patients receive full cardiac pharmacotherapy services: a pharmacist's call to arms.

While clinical trials have proven that use of certain cardiovascular drugs improves morbidity and mortality, these drugs are not widely used, they are by and large prescribed in suboptimal doses, and their benefit is further diminished by nonadherence. Pharmacists have the ability to improve the survival of patients with cardiovascular risks. This can only be accomplished through the efforts of the individual pharmacist and the further development of health-system management services. Pharmacists need to leverage their access to patients, their large patient base, and their knowledge of refill dates to improve patient care. Support and development of more pharmacist-directed anticoagulation, hyperlipidemia, and hypertension clinics are also needed.

Cardiovascular Agents↗